Chimeric nanoparticles for targeting mitochondria in cancer cells. Issue 4 (21st January 2022)

• Record Type: Journal Article
• Authors: Bajpai, Aman; Desai, Nakshi Nayan; Pandey, Shalini; Shukla, Chinmayee; Datta, Bhaskar; Basu, Sudipta
• Is Part Of: Nanoscale advances. Volume 4:Issue 4(2022)
• Page Start: 1112
• Page End: 1118
• Publication Date: 2022-01-21
• Subjects: 620.5
• DOI: 10.1039/d1na00644d
• Languages: English
• ISSNs: 2516-0230

Abstract

Abstract : Mitochondrial dysfunction is implicated in myriad diseases, including cancer. Abstract : Mitochondrial dysfunction is implicated in myriad diseases, including cancer. Subsequently, targeting mitochondrial DNA (mt-DNA) in cancer cells has emerged as an unorthodox strategy for anti-cancer therapy. However, approaches targeting only one component of the mitochondrial "central dogma" can be evaded by cancer cells through various mechanisms. To address this, herein, we have engineered mitochondria-targeting cholesterol-based chimeric nanoparticles (mt-CNPs) consisting of cisplatin, camptothecin, and tigecycline, which can simultaneously impair mt-DNA, mitochondrial topoisomerase I (mt-Top1), and mitochondrial ribosomes. mt-CNPs were characterized as being positively charged, spherical in shape, and 187 nm in diameter. Confocal microscopy confirmed that mt-CNPs efficiently localized into the mitochondria of A549 lung cancer cells within 6 h, followed by mitochondrial morphology damage and the subsequent generation of reactive oxygen species (ROS). mt-CNPs showed remarkable cancer-cell killing abilities compared to free-drug combinations in A549 (lung), HeLa (cervical), and MCF7 (breast) cancer cells. These mitochondria-targeting lipidic chimeric nanoparticles could be explored further to impair multiple targets in mitochondria, helping researchers to gain an understanding of mitochondrial translational and transcriptional machinery and to develop new strategies for cancer therapy.